None listed
Conditions
Interventions
Intervention1: CUQ1720: Oral administration of CUQ1720 capsules twice a day for 84 days
Intervention2: AK-CQAB-0520
: Oral administration of AK-CQAB-0520 capsules twice a day for 84 days
Control Inte
Sponsors
Akay Natural Ingredients Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Subjects categorized as AR according to international guideline of American Academy of Allergy Asthma and Immunology 2. History of allergic rhinitis (persistent or seasonal) symptoms for at least two consecutive years. 3. No antibiotics use within 1 month prior to entering the study or during the study 4. If female of childbearing age, willing to use an acceptable form of birth control measure, should be stable for past 3 months prior to baseline and throughout the Study 5. Must be willing and able to give informed consent and comply with the study procedures
Exclusion criteria
Exclusion criteria: 1. Asthmatic subjects who required long term inhaled or systemic corticosteroids within the previous 30 days 2. Subjects with nasal polyps and chronic respiratory tract infections 3. Subjects having symptoms of viral infection, including COVID-19 infection 4. Subjects with deteriorating health status at the time of enrolment, rapid weight loss, terminal disease, significant chronic disease (e.g., chronic diarrhoea, gastro-intestinal diseases, irritable bowel syndrome) 5. History of Recent blood donation, Immunodeficiency disease (e.g., human immunodeficiency virus [HIV] infection) 6. Concomitant medication/supplement which could affect the study 7. Any contraindication to blood sampling 8. Pregnant and lactating women 9. Subjects allergic to herbal products, nuts or any component of the study product 10. Currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study 11. Any additional condition(s) that in the Investigators opinion would warrant exclusion from the study or prevent the subject from completing the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Allergic Rhinitis (AR) SymptomsTimepoint: Day 0, Day 28, Day 84 | — |
Secondary
| Measure | Time frame |
|---|---|
| Over all health benefitsTimepoint: Day 0, Day 28, Day 84;Over all Safety of the test productsTimepoint: Day 0, Day 28, Day 84 | — |
Countries
India
Contacts
Public ContactJestin V Thomas
Leads Clinical Research and Bio Services Pvt. Ltd
Outcome results
None listed